Phase II KarMMa: Idecabtagene Vicleucel for R/R Multiple Myeloma

Source: 2020 ASCO Virtual Scientific Meeting*
Download Slideset
May 29-31, 2020; Online at meetings.asco.org/am
Idecabtagene vicleucel therapy resulted in CR/sCR responses in one third of patients with heavily pretreated R/R MM with durability approaching 2 years.
Format: Microsoft PowerPoint (.ppt)
File Size: 227 KB
Released: June 4, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Karyopharm Therapeutics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings